| Budget Amount *help |
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2012: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2011: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2010: ¥9,230,000 (Direct Cost: ¥7,100,000、Indirect Cost: ¥2,130,000)
|
|---|
| Research Abstract |
We have reported that UV-inactivated Sendai virus particles (hemagglutinating virus of Japan envelope; HVJ-E) have multiple anti-tumor activities. Clinical application of HVJ-E has been started to evaluate the safety and efficacy of the particle in cancer patients. To enhance the anti-tumor activities, we attempted to incorporate therapeutic molecules into HVJ-E. As a result, HVJ-E containing IL2 or IL-12 gene enhanced anti-tumor immunity. HVJ-E having IL-12 polypeptide on the surface was developed and was more effective for the treatment of melanoma than original HVJ-E alone. Rad51 siRNA incorporated into HVJ-E augmented the effect of cancer treatment when combined with anti-tumor reagent, dacarbazine.
|
